- Open Access
Serum glomerular albumin permeability activity: association with rapid progression to end-stage renal disease in focal segmental glomerulosclerosis
© Pudur et al. 2016
Received: 13 January 2016
Accepted: 30 March 2016
Published: 11 April 2016
Focal segmental glomerulosclerosis (FSGS) is a major cause of renal failure. Sera of some FSGS patients increase glomerular albumin permeability (Palb) during in vitro testing and cause proteinuria in experimental animals.
To determine whether permeability activity of FSGS serum (Palb activity) is associated with rate of progression to renal replacement therapy (RRT).
This is an observational study based on medical and demographic information and Palb activity testing.
Studies were performed at Medical College of Wisconsin.
Serum was submitted by patients’ nephrologists for measurement of Palb activity. Each patient had had a biopsy diagnosis of FSGS, had reached ESRD and was on dialysis or had a functioning transplant.
Palb activity, clinical characteristics and time between biopsy diagnosis and RRT (T-RRT) were recorded for each patient.
Palb activity was measured using established in vitro techniques.
Palb and T-RRT were inversely correlated. Neither Palb nor T-RRT varied with demographics or medications. Kaplan–Meier survival curves showed that patients with Palb ≥ 0.5 progressed to RRT more rapidly than others.
Only patients who had reached RRT were included. Limited clinical information was available for each patient. Central verification of biopsy characteristics was not performed and detailed descriptions of renal histology were not available.
Palb activity is associated with the rate of progression to RRT in patients with FSGS. Additional observations will be needed to verify that Palb activity predicts prognosis and is useful in stratifying patients for clinical decision making or treatment trials.
Focal segmental glomerulosclerosis (FSGS) is characterized by nephrotic-range proteinuria and a distinctive histopathological appearance on biopsy. FSGS accounts for a third of primary nephrotic syndrome in adults and a quarter in children. The etiology of FSGS is unknown in the majority of cases, but can be secondary to genetic abnormalities, decreased nephron number, hyperperfusion/hyperfiltration, reflux nephropathy, obesity, viral infections, drugs and malignancy (Daskalakis and Winn 2006; D’Agati et al. 2011). The lesion in FSGS is progressive and leads to a need for renal replacement therapy (RRT) in 50–75 % of patients over a 10-year period (Braun et al. 2008; Korbet 2012; Franceschini et al. 2003; Burgess 1999). In a subset of patients with FSGS, the progression to RRT is rapid and progression to end-stage renal disease occurs within 3 years. A measure by which one could identify patients who are at high risk for rapid progression to RRT would allow modification of the approach to therapy for the individual patient. In addition, a tool to identify these subjects would be valuable in designing and interpreting clinical trials on FSGS.
We have developed albumin permeability (Palb) testing as a functional assay to provide a sensitive measure of the integrity of the glomerular macromolecular permeability barrier. Experimental values for Palb activity vary from 0, normal, to 1.0, representing maximal loss of barrier function (Savin et al. 1992). We have used this test to determine the effect of patient serum on glomerular barrier function. We have shown increased permeability activity (Palb activity or Palb) in samples of serum or plasma from renal transplant recipients with recurrent FSGS (Cattran et al. 2003; Savin et al. 2008). Palb activity is stable over time (Cattran et al. 2003; Savin et al. 1996, 2008) and is not affected by treatment with cyclosporine even when there is remission of nephrotic syndrome and is diminished by plasmapheresis (Savin et al. 1996). The injurious effect of serum as well as the occurrence of proteinuria in experimental animals after injection of serum, plasma or plasma fractions, and remission of post-transplant proteinuria after plasmapheresis or immunoadsorbtion has led us to hypothesize that a circulating factor is responsible for recurrence of FSGS in allografts (Savin et al. 1996; Sharma et al. 2002, 2004a, b; McCarthy et al. 2010; Zimmerman 1984). The aim of the current study was to determine if high Palb activity in patients with FSGS is associated with rapid progression to RRT in native kidneys.
Albumin permeability (Palb) activity was determined using serum samples submitted to the Center for Glomerular Pathophysiology at the Medical College of Wisconsin in the course of clinical evaluation of FSGS. All research activities were approved by the Human Subjects Committee of the Medical College of Wisconsin and were in compliance with the Helsinki Declaration. Samples were frozen at the site of collection and shipped to the study site by overnight carrier and remained frozen until they were thawed for analyses. Samples submitted from January 2001 through December 2004 were included. Inclusion criteria were diagnosis of primary FSGS as indicated on renal biopsy report, progression to renal replacement therapy (RRT) and availability of data including patient demographics, laboratory data, renal biopsy diagnosis, date of renal biopsy, date of initiation of dialysis or transplant and medications prescribed at the time the serum specimen was collected. Data regarding the duration of symptoms and information about medical therapy given prior to serum sample collection were not available. Patients with incomplete data and those who had not progressed to RRT were excluded. Values from samples obtained after plasmapheresis therapy were excluded because we have shown that this therapy decreases Palb activity (Savin et al. 1996). No information regarding renal function at the time of the biopsy, reason for performing the biopsy, details of renal histology, or classification of the pattern of FSGS was available. Time to renal replacement therapy (T-RRT) was defined as the duration between the date of biopsy diagnosis of FSGS to one of the following: (a) the date of initiation of dialysis, (b) the date of renal transplantation or (c) the date when GFR was <15 ml/min as estimated by MDRD formula for adults and Schwartz formula for children. Rapid progression was defined as the progression to RRT within 3 years of diagnosis. This cut-off was chosen because it is commonly used in the pediatric literature as a parameter associated with high risk for post-transplant recurrence (Artero et al. 1994).
Albumin permeability (Palb) assay
Palb is a continuous dimensionless variable that ranges from 0 to 1. Palb testing was carried out under standard conditions (Savin et al. 1992, 1996). Briefly, glomeruli were isolated from the renal cortex of normal rats. Isolation/incubation medium was isotonic and contained bovine albumin, 5 gm/dl, as an oncotic agent. Glomeruli were incubated for 10 min at 37 °C in medium to which patient serum, 2 % vol/vol, had been added or in control medium. Palb was calculated as previously described (Sharma et al. 2000). In the current study, Palb activity of ≥0.5 was used to define high activity. This cutoff value is consistent with our practice for interpretation of values for individual patients and is the 95 % confidence limit for values from normal serum or sera of patients with non-glomerular disease (Savin et al. 1996). We performed additional analyses in which patients were stratified using Palb activity of ≥0.4 to ≥0.7. All measurements were carried out without knowledge of the sample being tested and both positive and negative control samples were tested in each assay.
Continuous variables were summarized as mean ± SD. Univariate correlations were evaluated using Pearson correlation analysis. Group comparisons were performed using Student’s t test. The Chi squared test was used to investigate changes in proportion of categorical variables. Odds ratio was used to measure the association of Palb with T-RRT. Renal survival was investigated using Kaplan–Meier survival curves stratified by time compared between groups using the log-rank test. In addition, a latent class regression model was fitted to the data to detect heterogeneity of associations between Palb and T-RRT. Statistical analysis was performed using SPSS 20.0 software (SPSS Inc., Chicago, IL) and SAS version 9.1(SAS Institute Inc., Cary, NC). A p-value of <0.05 was considered statistically significant.
Stratified by Palb
Stratified by T-RRT
Palb < 0.5
Palb ≥ 0.5
T-RRT < 3 years
T-RRT > 3 years
30.1 ± 17.2
29.7 ± 19.6
30.2 ± 16.2
30.3 ± 17.0
30.62 ± 16.7
Male gender, n (%)
Ethnicity, n (%)
Medications, n (%)
ACEI and/or ARB
Cyclosporine or tacrolimus
Relationships between Palb activity and T-RRT in FSGS
Latent class regression model
A latent class regression model for associations between Palb and T-RRT was applied and 2 distinct patterns were identified. In 14 patients, T-RRT was ≤3 months. These patients had advanced CKD at the time of biopsy as indicated by high serum creatinine. Palb activity was not significantly associated with T-RRT. In the remaining 66 subjects, in whom biopsies showing FSGS were performed when the GFR was higher, there was an inverse association between Palb and T-RRT described by the fitted regression equation, T-RRT = 7.10 − 4.96*Palb.
The clinical course in adults with primary FSGS is variable, with about half of adults progressing to RRT in 10 years (Braun et al. 2008; Korbet 2012; Franceschini et al. 2003; Burgess 1999). Currently, there is no good histological or biochemical marker that predicts outcome in FSGS. Histological variants have been described and attempts have been made to use histological classification to predict response to therapy and prognosis (Schwartz et al. 1999; Thomas et al. 2006; Chun et al. 2004; Barisoni 2012). The collapsing variant shows a more rapid progression compared to other histological classes but other histological variants including tip lesion do not predict either response to treatment or prognosis (Valeri et al. 1996; Detwiler et al. 1994; Couser 2005). The treatment of primary FSGS is based on the rationale that a humoral factor or factors derived from a dysregulated immune system are responsible for development of proteinuria. At present, the majority of therapeutic interventions depends on corticosteroids or other traditional immunosuppressive agents and is associated with a range of side-effects (Braun et al. 2008; Korbet 2012). Recent studies indicate that cyclosporine and mycophenolate mofetil each induce remission in some steroid resistant patients (Hogg et al. 2013). Other novel agents including adalimumab (anti-TNF alpha), galactose and a novel dual endothelin receptor blocker and angiotensin receptor blocker (DUET trial, Sparsentan) are in trials (Joy et al. 2010; Trachtman et al. 2011a, b, 2015). A biomarker that could be used to stratify FSGS patients according to risk for rapid progression would be useful in design and interpretation of such trials. Such a biomarker might eventually allow individualization of therapy according to the potential risks and benefit.
Strengths of this study include the fact that our unique sample included FSGS patients who had reached RRT at the time of testing for Palb. All FSGS patients whose samples we analyzed were included; there were no censored observations. Patients represented a wide range of rates of progression and included both genders, and included both children and adults as well as several ethnicities. However, the study has several limitations. First, the dataset was limited to a cohort of FSGS patients who had progressed to RRT. We did not include samples from patients who continued to have adequate GFRs at the time the sample was submitted. We had only limited information regarding the patients’ prior history. Our information regarding medications was limited to their current therapy at the time of serum sample. We collected the information regarding current medications to examine potential interference with the Palb activity assay. No other information about their treatment during the course of disease was available but it is likely that many patients had received corticosteroids. The low rates of immunosuppressive therapy may have reflected the fact that the majority had reached ESRD and were no longer on therapy directed at treatment of FSGS or nephrotic syndrome while others may never have received therapy. The small size of the sample does not permit analysis of potential medication effects but our prior work indicates that cyclosporine does not alter Palb (Cattran et al. 2003). An additional limitation arises from the fact that the sample may reflect referral bias as it relates to submission of the sample for Palb testing. The sample may include a disproportionate number of patients who had good access to health care and to physicians who were aware of the potential for Palb testing. It may also over-represent patients with prior post-transplant recurrence or those who are awaiting initial renal transplants.
We have used Palb to follow activity of plasma during sequential fractionation and to characterize the circulating permeability factor for recurrence of FSGS in allografts. The central role for a circulating permeability factor in FSGS is based on the observations of (a) early recurrence of nephrotic syndrome after transplantation, (b) development of albuminuria in rats after injection of serum from these patients, (c) response to plasma exchange and (d) occurrence of transient proteinuria in infants born to women with FSGS (Savin et al. 1996; Sharma et al. 2002, 2004a, b; McCarthy et al. 2010; Zimmerman 1984; Gohh et al. 2005; Kemper et al. 2001). We have described the circulating permeability factor as a hydrophobic sialoprotein with a molecular weight in the range of 30 kDa. It binds to galactose coated agarose beads and can be eluted using a galactose solution (Sharma et al. 2004a). We have used mass spectrometry to identify cardiotrophin-like cytokine factor-1 (CLCF-1) in active fractions and have shown that glomerular and podocyte responses to CLCF-1 parallel the responses to FSGS serum (McCarthy et al. 2010; Sharma et al. 2015). Another candidate for the FSGS “factor” has been identified by Wei and colleagues. They have reported that increased concentrations of soluble urokinase-type plasminogen activator receptor (suPAR) are present in FSGS plasma and propose that suPAR concentration predicts post-transplant recurrence (Wei et al. 2011). Additional molecules including hemopexin, angiopoietin-like-4 and CD80 are associated with nephrotic syndrome and have also been shown to cause proteinuria in experimental animals (Garin et al. 2010; Lennon et al. 2008; Clement et al. 2011) but do not appear to be relevant to FSGS. The severity of nephrotic syndrome or FSGS is generally classified as “steroid sensitive”, “steroid resistant” or “steroid dependent” and according to the response to cytotoxic or immunosuppressive agents. These categories are necessarily applied only post hoc and cannot be used to guide initial treatment. Likewise, even within categories defined by response to therapy, there is no clear association between clinical parameters and progression of renal failure. There are no reports of a quantitative method for stratifying risk of rapid progression to RRT.
We have proposed that Palb activity ≥0.5 reflects the presence of a high concentration of circulating permeability factor(s) which causes significant glomerular injury and rapid progression in FSGS. Palb activity was ≥0.5 in 38 % of 26 children with newly diagnosed nephrotic syndrome 2 of whom were later diagnosed with FSGS. In that sample, Palb but did not differ between steroid sensitive and steroid resistant patients (Trachtman et al. 2004). We have found Palb activity ≥0.5 in 20–38 % in additional cohorts of FSGS (Savin et al. 1996; Trachtman et al. 2004). We previously reported that patients in whom FSGS recurred after transplantation had a higher Palb (0.47 ± 0.06) compared to that of FSGS patients who did not recur (0.14 ± 0.06). A Palb value of 0.5 permitted risk stratification, with 86 % of patients with Palb value of ≥0.5 developing recurrence versus only 17 % with Palb < 0.5 (Savin et al. 1996). In an independent sample of patients awaiting transplantation, Palb was greater than 0.6 in 9 of 10 patients with prior recurrence or rapid progression to ESRD (mean Palb 0.76 ± 0.21, n = 10) (Gohh et al. 2005). Testing Palb activity is currently available on a limited scale in our laboratory. It may provide an opportunity to evaluate FSGS patients using a non-invasive test. Measurement of a single molecule in the circulation may eventually supplant this functional assay, but the identity of active molecules in FSGS is currently being debated. In addition, any specific assay will risk missing a previously unidentified injurious molecule. The Palb assay may be a valuable tool both in designing and interpreting clinical research trials on FSGS. Prospective validation of our findings in a trial with defined selection criteria will be required prior to the general use of Palb activity for establishing prognosis in patients with FSGS.
In summary, our results indicate that high Palb activity is associated with rapid progression to RRT in biopsy proven FSGS. We suggest that Palb activity may be useful for risk stratification in future clinical trials of aggressive therapy or novel therapy in FSGS. Further studies will be required before Palb activity can be used to provide specific prognosis or dictate therapy in individual patients.
The roles of the authors are as follows: SP designed the study, carried out data collection and analysis and wrote the initial manuscript. ST and HD performed statistical analyses. TS provided additional analyses and major revisions of the manuscript. MS performed all Palb analyses and directed the study design. RS, ETM and VJS participated in study design and review and revisions of the manuscript. All authors read and approved the final manuscript.
The study was supported in by NIH Grants R01 DK 43752 and DK R21 00292588 (Savin), DK 1RO1 DK064969 (McCarthy) and from the VA BX001037 (Savin) and funds from the Midwest Biomedical Research Foundation (Savin, Sharma). This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Artero ML, Sharma R, Savin VJ, Vincenti F (1994) Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 23(4):574–581View ArticleGoogle Scholar
- Barisoni L (2012) Podocyte biology in segmental sclerosis and progressive glomerular injury. Adv Chronic Kidney Dis 19(2):76–83View ArticleGoogle Scholar
- Braun N, Schmutzler F, Lange C et al (2008) Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev 3:CD003233Google Scholar
- Burgess E (1999) Management of focal segmental glomerulosclerosis: evidence-based recommendations. Kidney Int 55:S26–S32View ArticleGoogle Scholar
- Cattran D, Neogi T, Sharma R, McCarthy ET, Savin VJ (2003) Serial estimates of serum permeability activity and clinical correlates in patients with native kidney focal segmental glomerulosclerosis. J Am Soc Nephrol 14(2):448–453View ArticleGoogle Scholar
- Chun M, Korbet S, Schwartz M, Lewis EJ (2004) Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 15:2169–2177View ArticleGoogle Scholar
- Clement LC, Avila-Casado C, Maće C et al (2011) Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephritic syndrome. Nat Med 17(1):117–122View ArticleGoogle Scholar
- Couser W (2005) Recurrent glomerulonephritis in the renal allograft: an update of selected areas. Exp Clin Transplant 3(1):283–288Google Scholar
- D’Agati VD, Kaskel FJ, Falk RJ (2011) Focal segmental glomerulosclerosis. N Engl J Med 365(25):2398–2411View ArticleGoogle Scholar
- Daskalakis N, Winn MP (2006) Focal and segmental glomerulosclerosis: varying biological mechanisms underlie a final histopathologic end point. Semin Nephrol 26:89–94View ArticleGoogle Scholar
- Detwiler RK, Falk RJ, Hogan SL, Jennette JC (1994) Collapsing glomerulopathy: a clinically and pathologically distinct variant of focal segmental glomerulosclerosis. Kidney Int 45:1416–1424View ArticleGoogle Scholar
- Franceschini N, Hogan SL, Falk RJ (2003) Primum non nocere: should adults with idiopathic FSGS receive steroids? Sem Nephrol 23:229–233View ArticleGoogle Scholar
- Garin EH, Mu W, Arthur JM et al (2010) Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int 78(3):296–302View ArticleGoogle Scholar
- Gohh RY, Yango AF, Morrissey PE et al (2005) Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant 5(12):2907–2912View ArticleGoogle Scholar
- Hogg RJ, Friedman A, Greene T et al (2013) Renal function and proteinuria after successful immunosuppressive therapies in patients with FSGS. Clin J Am Soc Nephrol 8(2):211–218View ArticleGoogle Scholar
- Joy MS, Gipson DS, Powell L et al (2010) Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis 55(1):50–60View ArticleGoogle Scholar
- Kemper MJ, Wolf G, Müller-Wiefel DE (2001) Transmission of glomerular permeability factor from a mother to her child. N Engl J Med 344(5):386–387View ArticleGoogle Scholar
- Korbet SM (2012) Treatment of primary FSGS in adults. J Am Soc Nephrol 23(11):1769–1776View ArticleGoogle Scholar
- Lennon R, Singh A, Welsh GI et al (2008) Hemopexin induces nephrin-dependent reorganization of the actin cytoskeleton in podocytes. J Am Soc Nephrol 19(11):2140–2149View ArticleGoogle Scholar
- McCarthy ET, Sharma M, Savin VJ (2010) Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 5(11):2115–2121View ArticleGoogle Scholar
- Savin VJ, Sharma R, Lovell HB, Welling DJ (1992) Measurement of albumin reflection coefficient in isolated rat glomeruli. J Am Soc Nephrol 3:1260–1269Google Scholar
- Savin VJ, Sharma R, Sharma M et al (1996) Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 334:878–883View ArticleGoogle Scholar
- Savin VJ, McCarthy ET, Sharma R, Charba D, Sharma M (2008) Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl Res 151:288–292View ArticleGoogle Scholar
- Schwartz MM, Evans J, Bains R, Korbet SM (1999) Focal segmental glomerulosclerosis: prognostic implications of the cellular lesion. J Am Soc Nephrol 10:1900–1907Google Scholar
- Sharma R, Sharma M, McCarthy ET, Ge XL, Savin VJ (2000) Components of normal serum block the focal segmental glomerulosclerosis factor activity in vitro. Kidney Int 58:1973–1979View ArticleGoogle Scholar
- Sharma M, Sharma R, Reddy SR, McCarthy ET, Savin VJ (2002) Proteinuria after injection of human focal segmental glomerulosclerosis factor. Transplantation 73:366–372View ArticleGoogle Scholar
- Sharma M, Sharma R, McCarthy ET, Savin VJ (2004a) The focal segmental glomerulosclerosis permeability factor: biochemical characteristics and biological effects. Exp Biol Med (Maywood) 229(1):85–98Google Scholar
- Sharma R, Sharma M, Savin VJ, McCarthy ET (2004b) The focal segmental glomerulosclerosis permeability factor: biochemical characteristics and biological effects. Exp Biol Med 229:85–98Google Scholar
- Sharma M, Zhou J, Gauchat JF, Sharma R, McCarthy ET, Srivastava T, Savin VJ (2015) Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier. Transl Res 166(4):384–398View ArticleGoogle Scholar
- Thomas DB, Franceschini N, Hogan SL et al (2006) Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 69:920–926View ArticleGoogle Scholar
- Trachtman H, Greenbaum LA, McCarthy ET et al (2004) Glomerular permeability activity: prevalence and prognostic value in pediatric patients with idiopathic nephritic syndrome. Am J Kidney Dis 44:604–610View ArticleGoogle Scholar
- Trachtman H, Vento S, Gipson D et al (2011a) Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design. BMC Nephrol 12:8View ArticleGoogle Scholar
- Trachtman H, Fervenza FC, Gipson DS et al (2011b) A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 79(11):1236–1243View ArticleGoogle Scholar
- Trachtman H, Vento S, Herreshoff E, Radeva M, Gassman J, Stein DT, Savin VJ, Sharma M, Reiser J, Wei C, Somers M, Srivastava T, Gipson DS (2015) Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group. BMC Nephrol 16:111View ArticleGoogle Scholar
- Valeri A, Barisoni L, Appel GB, Seigle R, D’Agati V (1996) Idiopathic collapsing focal segmental glomerulosclerosis: a clinicopathologic study. Kidney Int 50:1734–1746View ArticleGoogle Scholar
- Wei C, El Hindi S, Li J et al (2011) Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17(8):952–960View ArticleGoogle Scholar
- Zimmerman SW (1984) Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomerular sclerosis after renal transplantation. Clin Nephrol 22:32–38Google Scholar